AstraZeneca upgraded by Jefferies with a new price target
$AZN
Biotechnology: Pharmaceutical Preparations
Health Care
Jefferies upgraded AstraZeneca from Hold to Buy and set a new price target of $80.00 from $66.50 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/20/2024 | Sell → Neutral | UBS | |
| 11/6/2024 | Sell → Hold | Deutsche Bank | |
| 9/13/2024 | Hold → Sell | Deutsche Bank | |
| 5/30/2024 | $97.00 | Buy | Goldman |
| 4/16/2024 | Sell → Hold | Deutsche Bank | |
| 2/8/2024 | Hold → Sell | Deutsche Bank | |
| 1/23/2024 | $85.00 | Overweight | Morgan Stanley |
| 1/16/2024 | Sell | UBS |
Upgrade to full year 2024 guidance underpinned by strong underlying growth momentum AstraZeneca: Revenue and EPS summary 9M 2024 % Change Q3 2024 % Change $m Actual CER1 $m Actual CER - Product Sales 37,576 16 19 12,947 18 20 - Alliance Revenue 1,498 49 50 559 48 50 - Collaboration Revenue 108 (66) (66) 59 (39) (40) Total Revenue 39,182 16 19 13,565 18 21 Reported EPS $3.57 11 21
ODD and RPDD granted by the FDA and ODD granted by the European Commission to UCART22 for the treatment of ALLODD granted by the FDA to CLLS52 (alemtuzumab) for ALL treatmentCash position of $273 million as of June 30, 20241; cash runway projection into 2026 NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided business updates and reported financial results for the six-month period ending June 30, 2024. "Over the past months, we have achieved a significant milestone with the granting of ODD designations by
Strong underlying growth supports FY 2024 guidance upgrade, with both Total Revenue and Core EPS now expected to increase by a mid teens percentage at CER1 AstraZeneca: Revenue and EPS summary H1 2024 % Change Q2 2024 % Change $m Actual CER $m Actual CER - Product Sales 24,629 15 18 12,452 14 18 - Alliance Revenue 939 50 50 482 42 42 - Collaboration Revenue 49 (78) (78) 4 (98) (98) Total Revenue 25,617 15 18 12,938 13 17
SC 13G/A - ASTRAZENECA PLC (0000901832) (Subject)
SC 13G/A - ASTRAZENECA PLC (0000901832) (Subject)
ROCKVILLE, Md., June 6, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, will lead the Company's global clinical development efforts and serve as a member of I-Mab's Executive Leadership Team. "I am pleased to welcome Dr. Phillip Dennis as our Chief Medical
In recognition of Rare Disease Day on February 29, Alexion welcomes people across the country to join the international colourUp4RARE challenge and learn more about the impact of rare diseases on an estimated three million Canadian families MISSISSAUGA, ON, Feb. 26, 2024 /CNW/ - Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, is marking Rare Disease Day on February 29 by launching colourUp4RARE. The international campaign aims to raise awareness of how to improve quality of life of people living with rare diseases in Canada, and around the world. Approximately,
NIH data show that globally less than 2% of genetic information being studied today originates from people of African ancestry1 The newly established Diaspora Human Genomics Institute (DHGI) will manage the Together for CHANGE initiative, which aims to increase available genomic data for people of African ancestry and enhance representation in STEM careers NASHVILLE, Tenn. and TARRYTOWN, N.Y. and WILMINGTON, Del. and BAGSVAERD, Denmark and BASEL, Switzerland, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Meharry Medical College, along with partners Regeneron Genetics Center® (RGC™), AstraZeneca, Novo Nordisk, and Roche, today announced the launch of the Together for CHANGE™ ("Changing Healthcare for
6-K - ASTRAZENECA PLC (0000901832) (Filer)
6-K - ASTRAZENECA PLC (0000901832) (Filer)
6-K - ASTRAZENECA PLC (0000901832) (Filer)
UBS upgraded AstraZeneca from Sell to Neutral
Deutsche Bank upgraded AstraZeneca from Sell to Hold
Deutsche Bank downgraded AstraZeneca from Hold to Sell
- Proprietary data and samples from TRACERx and Achilles' Material Acquisition Platform (MAP) will be transferred to AstraZeneca under the Transaction - - Conclusion of Strategic Review - LONDON, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL) today announced that it has transferred the commercial license of data and samples from the TRACERx® Non-Small Cell Lung Cancer (NSCLC) study to AstraZeneca (NASDAQ:AZN). TRACERx (TRAcking Cancer Evolution through therapy (Rx)), led by Professor Charles Swanton at University College London (UCL), UK, is one of the largest tumor evolution studies to generate deep sequencing multi-region and multi-time-point genetic data
The agreement is a critical step in ensuring paediatric patients living with NF1 PN have public access to Koselugo, the only approved therapy in Canada for this rare disease MISSISSAUGA, ON, Dec. 18, 2024 /CNW/ - Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, has entered into a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for Koselugo for the treatment of paediatric patients aged two years and above with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). With the agreement in place with the pCPA, individual provinces and territories may now initiate the process to list Koselugo on their formularies, the
Tracer Biotechnologies, a next-generation diagnostics company, today announced a multi-year project with AstraZeneca (NASDAQ:AZN). The agreement will enable AstraZeneca to use Tracer's circulating tumor DNA (ctDNA) monitoring technology for clinical trials. Tracer has developed a proprietary platform for tumor-informed ctDNA detection based on digital polymerase chain reaction (PCR). Tracer's platform optimizes ctDNA detection, enabling cost-effective, precise, and scalable testing for patients as an alternative to radiographic imaging. "We are entering a new era of oncology where patients will no longer have to wait for costly and imprecise radiographic scans to assess treatment and di